Certara (CERT) Stock Forecast & Price Target

Certara is viewed favorably because its differentiated biosimulation and MIDD software franchise is gaining traction, with software bookings up 20% y/y and 1Q26 Software revenue of $49.7M growing 7.2% y/y. The post-R&MW divestiture sharpens strategic focus, reduces bookings volatility, and should support a stronger long-term growth and margin profile, while software strength from Simcyp, Phoenix, and Chemaxon suggests the core platform is outperforming the broader business. Although Services revenue declined 4.1% y/y to $57.2M, management’s improving operational discipline and better end-market conditions should help margins move toward the 30% to 32% range and support more durable financial improvement.

Certara is facing a negative fundamental setup because the R&MW divestiture and mixed 1Q26 results have not delivered the clear financial upside investors likely expected, leaving FY26 revenue and EBITDA guidance reset lower to $395M and $119M. Execution risk remains elevated as services softness, lingering regulatory-adjacent volatility, and a 2H-weighted FY26 guide reduce visibility, while margins are pressured by continued investment in AI/MIDD initiatives and operating expense growth. Even with solid backlog conversion and a stronger core biosimulation moat, competition, only partial shift toward software, and a slower-than-hoped recovery path support a cautious outlook.